Zenas BioPharma, Inc.
ZBIO
Jodie situation report
Zenas BioPharma, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 5 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 17 directly disclosed connections are confirming.
- ZBIO's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if ZBIO's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind ZBIO
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
VRDNViridian Therapeutics, Inc.partnerMar 16, 2026 ▾
“Partnered Regional Programs We also have in-licensed the development and commercialization rights to ZB001 (also known as VRDN-001), an IGF-1R monoclonal antibody, and related programs from Viridian Therapeutics, Inc.”
ALMSAlumis Inc.competitorMar 16, 2026 ▾
“There are several TYK2 inhibitor programs in clinical development in the US, including the following Phase 3 programs: zasocitinib, a peripheral acting TYK2 inhibitor being developed by Takeda Pharmaceutical Company Limited, envudeucitinib, a brain-penetrant…”
Depended on by
DNTHDianthus Therapeutics, Inc.partnerMay 5, 2026 ▾
“26 Licensing Agreements In June 2022, we executed a license agreement with Zenas BioPharma, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 18 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ZBIO is currently a Follower in the organic co-movement group Diversified Financials & Services. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.